SG Americas Securities LLC Sells 15,672 Shares of Hologic, Inc. (NASDAQ:HOLX)

SG Americas Securities LLC lowered its holdings in Hologic, Inc. (NASDAQ:HOLX) by 77.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,437 shares of the medical equipment provider’s stock after selling 15,672 shares during the period. SG Americas Securities LLC’s holdings in Hologic were worth $320,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in HOLX. Nisa Investment Advisors LLC grew its holdings in shares of Hologic by 44.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider’s stock valued at $4,595,000 after acquiring an additional 19,688 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in Hologic by 80.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 32,588 shares of the medical equipment provider’s stock valued at $2,349,000 after purchasing an additional 14,487 shares during the last quarter. Atwood & Palmer Inc. grew its stake in Hologic by 0.5% in the fourth quarter. Atwood & Palmer Inc. now owns 357,735 shares of the medical equipment provider’s stock valued at $25,789,000 after purchasing an additional 1,714 shares in the last quarter. LaFleur & Godfrey LLC increased its position in shares of Hologic by 2.9% during the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider’s stock worth $9,399,000 after purchasing an additional 3,655 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in shares of Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock worth $343,000 after purchasing an additional 188 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of a number of analyst reports. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Raymond James boosted their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. upped their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Monday, January 13th. Finally, Wolfe Research initiated coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Eight equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $71.58 on Wednesday. The company’s 50 day moving average price is $73.05 and its two-hundred day moving average price is $77.98. Hologic, Inc. has a 12-month low of $68.61 and a 12-month high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a market cap of $16.16 billion, a PE ratio of 21.50, a PEG ratio of 2.35 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the firm earned $0.89 EPS. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.